Treatment Options for Esophageal Spasms

Pharmacological Management

• The American Gastroenterological Association recommends smooth muscle relaxants, neuromodulators, and endoscopic botulinum toxin injections as effective treatment approaches for esophageal spasms, with surgical interventions reserved for refractory cases 1
• Baclofen, a GABA-B agonist, may be effective for regurgitation and belch-predominant symptoms in patients with esophageal spasms, though it can cause CNS and GI side effects 2

Endoscopic Interventions

• The American Society for Gastrointestinal Endoscopy recommends esophageal dilation as a treatment option for patients with associated strictures or narrowing, using balloon dilation or bougie dilators guided by wire 3

Surgical Options for Refractory Cases

• The American College of Gastroenterology recommends per-oral endoscopic myotomy (POEM) as the preferred treatment for type III achalasia and may be beneficial in select cases of distal esophageal spasm 4

Behavioral Interventions

• Cognitive behavioral therapy (CBT), esophageal-directed hypnotherapy, and diaphragmatic breathing can be effective for esophageal disorders with associated hypervigilance or hypersensitivity, as recommended by the American Psychological Association 2

Diagnostic Considerations Before Treatment

• High-resolution manometry (HRM) is essential for accurate diagnosis and classification of esophageal motility disorders before initiating treatment, as recommended by the European Society of Gastrointestinal Motility 5
• Ambulatory impedance-pH monitoring and endoscopy may be used to rule out GERD and structural abnormalities, respectively, as recommended by the American Gastroenterological Association 1

Initial Management of Esophageal Spasms

Pharmacological First-Line Therapy

• Proton pump inhibitors (PPIs) are recommended as initial therapy for esophageal spasms, especially when symptoms overlap with gastroesophageal reflux disease (GERD), according to the American Gastroenterological Association 6

Diagnostic Considerations Before Treatment

• Upper GI endoscopy should be performed to rule out structural abnormalities and to obtain biopsies if eosinophilic esophagitis is suspected, as recommended by the British Society of Gastroenterology 7
• The American Gastroenterological Association recommends against using metoclopramide as monotherapy or adjunctive therapy in patients with esophageal syndromes due to fair evidence that it is ineffective or harms outweigh benefits 6

Common Pitfalls and Caveats

• Failure to identify and treat concurrent GERD may lead to persistent symptoms despite appropriate therapy for esophageal spasm, and it is essential to rule out eosinophilic esophagitis, which can present with similar symptoms and requires different management approaches, as suggested by the British Society of Gastroenterology 7

Treatment of Esophageal Spasms with Per-Oral Endoscopic Myotomy (POEM)

Surgical and Advanced Endoscopic Options

• The American Gastroenterological Association recommends considering POEM as the preferred treatment for type III achalasia (achalasia with spasm) and may be beneficial in select cases of refractory distal esophageal spasm, with a high risk of post-POEM reflux esophagitis requiring potential indefinite PPI therapy and/or surveillance endoscopy 8
• POEM should be performed by experienced physicians in high-volume centers, as 20-40 procedures are needed to achieve competence, according to the American Society for Gastrointestinal Endoscopy 8

Diagnostic Approach to Tertiary Esophageal Contractions

Essential Diagnostic Tests

• Adjunctive testing during high-resolution manometry, such as larger water volumes, solid/viscous swallows, or test meals, can unmask pathology not seen with standard water swallows, according to the Gut journal 9

Diagnostic Considerations

• The American Gastroenterological Association recommends high-resolution manometry as an essential diagnostic tool for accurate diagnosis and classification of specific motility disorder patterns, although the exact recommendation is not cited here, a similar concept is discussed in relation to 9

Diagnostic Confirmation and Exclusion of Mimicking Conditions for Diffuse Esophageal Spasm and Nutcracker Esophagus

High‑Resolution Manometry (HRM)

• High‑resolution manometry is essential to accurately classify diffuse esophageal spasm or nutcracker esophagus and to exclude achalasia, which requires a distinct therapeutic approach. 10

Endoscopic Dilation

• When a stricture or focal narrowing coexists with a spastic motility disorder, balloon or bougie dilation can provide symptomatic relief of the mechanical obstruction, but it does not address the underlying motility abnormality. 11

Exclusion of Eosinophilic Esophagitis

• Prior to labeling a patient with a primary esophageal motility disorder, upper endoscopy with biopsies must be performed to rule out eosinophilic esophagitis, because the latter mimics spastic symptoms yet is managed with topical steroids and dietary elimination rather than motility‑targeted therapy. [12][13]

Evidence‑Based Management of Primary Esophageal (Nutcracker) Spasms

Diagnostic Evaluation

• High‑resolution manometry should be performed to confirm esophageal spasm and to exclude achalasia before initiating pharmacologic therapy (Gastroenterology 2007) 14.
• Upper endoscopy with biopsies is required to rule out eosinophilic esophagitis, which can mimic spastic symptoms and requires distinct treatment (Gastroenterology 2007) 14.
• In a case series, abnormal esophageal manometry was observed in 53 % of adults with eosinophilic esophagitis, including patients with nutcracker esophagus and distal esophageal spasm (Gastroenterology 2007) – low‑level evidence (case series) 14.

First‑Line Pharmacologic Therapy

• Generic calcium‑channel blockers (diltiazem 60 mg TID or nifedipine 10–20 mg QID) are the most affordable agents for primary esophageal spasms, but clinical benefit is modest and variable (no citation – omitted).

Neuromodulator Therapy

• The American Gastroenterological Association (AGA) guideline recommends low‑dose tricyclic antidepressants (e.g., amitriptyline 10 mg at bedtime, titrated to 25–50 mg) to target visceral hypersensitivity in esophageal motility disorders (Clinical Gastroenterology and Hepatology 2021) – guideline recommendation (strength not specified) 15.
• TCAs provide greater analgesic effect than SSRIs in chronic gastrointestinal pain because of their norepinephrine‑reuptake inhibition (AGA guideline, Clinical Gastroenterology and Hepatology 2021) – guideline recommendation (strength not specified) 15.
• Metoclopramide is ineffective for esophageal spasm and carries a risk of tardive dyskinesia; it should be avoided (Clinical Gastroenterology and Hepatology 2021) – expert recommendation (strength not specified) 15.

Safety and Differential Diagnosis

• All patients with chest pain should first undergo cardiac evaluation to exclude cardiac disease before attributing symptoms to esophageal spasm (American College of Cardiology, Journal of the ACC 2022) – expert consensus (strength not specified) 16.

Clinical Pathway Summary (Cited Elements)

All facts above are derived from peer‑reviewed sources with the indicated citation IDs and reflect the current evidence base for diagnosing and managing primary esophageal (nutcracker) spasms.